申请人:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
公开号:US20130251787A1
公开(公告)日:2013-09-26
Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A
4
hydrolase (LTA
4
H) inhibitors, leukotriene B
4
receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxgygenase activating protein (FLAP) inhibitors.
肺动脉高压(PAH)可以在易患该病的人群中预防,并且可以通过给予有效剂量的白细胞三烯抑制剂来治疗PAH患者。合适的抑制剂包括白细胞三烯A4水解酶(LTA4H)抑制剂、白细胞三烯B4受体(BLT1/BLT2)拮抗剂、5-脂氧合酶(5-LO)抑制剂和5-脂氧合酶激活蛋白(FLAP)抑制剂。